Invesco Ltd. Grows Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Invesco Ltd. grew its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 1,956.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 214,490 shares of the company's stock after acquiring an additional 204,061 shares during the quarter. Invesco Ltd. owned about 0.35% of Pulse Biosciences worth $3,734,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PLSE. Vanguard Group Inc. increased its position in Pulse Biosciences by 15.1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock worth $19,958,000 after purchasing an additional 150,506 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Pulse Biosciences by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after buying an additional 33,200 shares during the last quarter. Barclays PLC raised its position in shares of Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after buying an additional 23,738 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Pulse Biosciences during the 3rd quarter valued at approximately $378,000. Finally, Norges Bank acquired a new position in Pulse Biosciences in the fourth quarter valued at approximately $348,000. Hedge funds and other institutional investors own 76.95% of the company's stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.

Pulse Biosciences Trading Up 2.1 %

PLSE stock traded up $0.37 during mid-day trading on Friday, hitting $17.54. 12,740 shares of the company were exchanged, compared to its average volume of 197,866. Pulse Biosciences, Inc. has a 12-month low of $6.66 and a 12-month high of $25.00. The business has a fifty day simple moving average of $16.83 and a 200-day simple moving average of $18.03.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.